| Disproportionality Analysis of Tumour Lysis Syndrome (TLS) Associated with Bruton's Tyrosine Kinase Inhibitor (BTKi) using Food and Drug Administration Adverse Events Reporting … Z Zeba, A Shettigar, L Lukose, G Kaur, G Nair, N Haider, L Thomas, ... | 2 | 2022 |
| Purine antimetabolites associated Pneumocystis jirovecii pneumonia L Lukose, PM Shantaram, A Raj, G Nair, AM Shaju, V K. Subeesh Pharmacoepidemiology and drug safety 32 (11), 1244-1251, 2023 | 1 | 2023 |
| Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database VS Akhil T. Jacob, Ankitha Hari Kumar, Gayethri Halivana, Lipin Lukose ... British Journal of Clinical Pharmacology, 2023 | 1 | 2023 |
| Hidden danger: maize starch excipient allergy L Lukose, S Seth, K Sud, B Nankivell, MA Nicdao, RL Castelino Clin Exp Allergy 39, 1643-1651, 2009 | 1 | 2009 |
| Predictors and patterns of empirical antibiotic therapy and associated outcomes in COVID-19 patients: a retrospective study in a tertiary care facility in South India L Lukose, G Kaur, GA Abraham, K Khera, VK Subeesh, RL Castelino, ... Expert Review of Anti-infective Therapy 22 (5), 333-341, 2024 | | 2024 |
| Pulmonary related adverse events associated with bruton's tyrosine kinase inhibitor: A disproportionality analysis in a spontaneous reporting database SK Viswam, A Shettigar, Z Zeba, A Dhas, A Kheterpal, G Kaur, L Lukose PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 223-223, 2022 | | 2022 |
| Cytomegalovirus infection reactivation in multiple myeloma patients administered proteasome inhibitor-combination therapy: A disproportionality analysis in a spontaneous … G Kaur, L Lukose, BE Thomas, SK Viswam PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 595-596, 2022 | | 2022 |
| Triazole anti-fungals associated with acute pancreatitis: A disproportionality analysis in a spontaneous reporting database L Lukose, A Shaju, M Asif, SK Viswam PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 131-132, 2022 | | 2022 |
| Gastrointestinal adverse events associated with PI3K inhibitors: A disproportionality analysis of FDA adverse event reporting system SK Viswam, R Kamath, J Sharon, A Shivakumar, A Shenoy, L Lukose, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 454-455, 2022 | | 2022 |
| Gastrointestinal adverse events associated with hedgehog pathway inhibitors: A real-world pharmacovigilance study A Shivakumar, A Shenoy, J Sharon, R Kamath, L Lukose, G Kaur, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 593-593, 2022 | | 2022 |
| Cardiovascular adverse events associated with parp inhibitors: A disproportionality analysis of FDA adverse event reporting system SK Viswam, A Kheterpal, A Dhas, Z Zeba, A Shettigar, L Lukose, G Kaur PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 452-452, 2022 | | 2022 |
